Travere Therapeutics
TVTX
261 hedge funds and large institutions have $3.01B invested in Travere Therapeutics in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 90 increasing their positions, 93 reducing their positions, and 59 closing their positions.
46% more call options, than puts
Call options by funds: $86.6M | Put options by funds: $59.4M
3% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 93
4.32% less ownership
Funds ownership: 114.22% → 109.9% (-4.3%)
6% less funds holding
Funds holding: 278 → 261 (-17)
17% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 59
23% less capital invested
Capital invested by funds: $3.9B → $3.01B (-$893M)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$40.4M |
| 2 |
AC
Armistice Capital
New York
|
+$33.9M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$33.9M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$31.4M |
| 5 |
Janus Henderson Group
London,
|
+$27.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$58.3M |
| 2 |
Morgan Stanley
New York
|
-$33.3M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$26.7M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$22.5M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$21.9M |
TVTX Hedge Fund Activity: Q1 2026 in Review
261 of the 8,190 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2026, worth a combined $3.01B — down 23% from $3.9B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of TVTX and 49 opened new positions — a net loss of 10 holders — while 93 trimmed existing stakes and 90 added.
The largest buyer was Fidelity Investments, adding an estimated $40.4M. The largest seller was Adage Capital Partners, cutting an estimated $58.3M.
- 261 institutional investors held Travere Therapeutics (TVTX) as of Q1 2026, down from 278 in Q4 2025.
- Funds reported $3.01B of Travere Therapeutics stock for Q1 2026, down 23% quarter-over-quarter.
- 49 funds opened new Travere Therapeutics positions in Q1 2026 and 59 closed out, a net change of -10 holders.
- The largest Travere Therapeutics buyer in Q1 2026 was Fidelity Investments, an estimated $40.4M added.
- The largest Travere Therapeutics seller in Q1 2026 was Adage Capital Partners, an estimated $58.3M sold.
Based on aggregated 13F filings for Q1 2026.